Sipuleucel-T Found to Have Added Therapeutic Benefit in Prostate Cancer Patients

Sipuleucel-T Found to Have Added Therapeutic Benefit in Prostate Cancer Patients
The German Institute for Quality and Efficiency in Health Care (IQWiG), an independent scientific institute that examines the risks and benefits of medical interventions in patients, recently reported in a press release that sipuleucel-T (trade name Provenge), a cell-based cancer immunotherapy for prostate cancer has added benefit for prostate cancer patients’ clinical outcome. Sipuleucel-T is an

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *